Table 1.
Standardized Differences In The Full Cohort and Propensity-Matched Cohort
| Full Cohort | Matched | |||||||
|---|---|---|---|---|---|---|---|---|
| Covariate | No
Platelet Transfusion N=30449 |
Platelet Transfusion N=1065 |
Standardized Difference (%) |
p-value | No
Platelet Transfusion N=994 |
Platelet Transfusion N=994 |
Standardized Difference (%) |
p-value |
| Demographics | ||||||||
| Age | 62.4 (17.5) | 62.3 (15.2) | 0.5 | 0.888† | 62.8 (15.1) | 62.7 (15.2) | 0.4 | 0.935† |
| Male Sex | 17946 (58.9%) | 728 (68.4%) | 19.7 | <0.001‡ | 710 (72.1%) | 684 (69.4%) | 5.8 | 0.198‡ |
| White Race | 27419 (90.0%) | 962 (90.3%) | 0.9 | 0.764‡ | 896 (91.0%) | 890 (90.4%) | 2.1 | 0.642‡ |
| Laboratory Variables | ||||||||
| Albumin (g/dL) | 0.8 (1.6) | 1.6 (1.8) | 42.8 | <0.001† | 1.6 (1.8) | 1.5 (1.8) | 4.3 | 0.337† |
| Hemoglobin (g/dL) | 10.9 (1.9) | 10.1 (2.0) | 40.2 | <0.001† | 10.2 (1.9) | 10.2 (2.0) | 1.8 | 0.682† |
| INR | 1.3 (0.5) | 1.4 (0.6) | 30.2 | <0.001† | 1.4 (0.7) | 1.4 (0.6) | 2.3 | 0.608† |
| Platelet count (x 109/L) | 172.9 (81.8) | 72.8 (60.2) | 139.3 | <0.001† | 81.1 (50.1) | 77.5 (60.1) | 6.4 | 0.154† |
| Medications | ||||||||
| Aspirin | 16089 (52.8%) | 446 (41.9%) | 22.1 | <0.001‡ | 414 (42.0%) | 437 (44.4%) | 4.7 | 0.296‡ |
| Clopidogrel | 3568 (11.7%) | 77 (7.2%) | 15.4 | <0.001‡ | 83 (8.4%) | 76 (7.7%) | 2.6 | 0.563‡ |
| Factor Xa inhibitor | 53 (0.2%) | 3 (0.3%) | 2.3 | 0.439§ | 3 (0.3%) | 3 (0.3%) | 0.0 | 1.000§ |
| LMW heparin | 1885 (6.2%) | 43 (4.0%) | 9.8 | 0.004‡ | 39 (4.0%) | 39 (4.0%) | 0.0 | 1.000‡ |
| Thrombin inhibitor | 198 (0.7%) | 16 (1.5%) | 8.3 | 0.001‡ | 16 (1.6%) | 15 (1.5%) | 0.8 | 0.856‡ |
| Unfractionated heparin | 3074 (10.1%) | 72 (6.8%) | 12.0 | <0.001‡ | 71 (7.2%) | 70 (7.1%) | 0.4 | 0.930‡ |
| Warfarin | 6357 (20.9%) | 203 (19.1%) | 4.5 | 0.151‡ | 184 (18.7%) | 201 (20.4%) | 4.4 | 0.334‡ |
| Comorbidities | ||||||||
| Charlson score | 1.7 (2.1) | 2.2 (2.2) | 21.6 | <0.001† | 2.2 (2.4) | 2.2 (2.3) | 1.0 | 0.824† |
| SOFA score | 4.1 (3.3) | 8.7 (3.6) | 131.6 | <0.001† | 8.2 (3.9) | 8.4 (3.4) | 3.2 | 0.471† |
| AIDS | 27 (0.1%) | 0 (0.0%) | 4.2 | 1.000§ | 0 (0.0%) | 0 (0.0%) | 4.5 | 1.000§ |
| CHF | 4727 (15.5%) | 162 (15.2%) | 0.9 | 0.781‡ | 169 (17.2%) | 154 (15.6%) | 4.1 | 0.361‡ |
| Chronic pulmonary disease | 4584 (15.1%) | 117 (11.0%) | 12.1 | <0.001‡ | 111 (11.3%) | 114 (11.6%) | 1.0 | 0.832‡ |
| Connective tissue disease | 1217 (4.0%) | 27 (2.5%) | 8.2 | 0.016‡ | 21 (2.1%) | 25 (2.5%) | 2.7 | 0.551‡ |
| Dementia | 771 (2.5%) | 11 (1.0%) | 11.3 | 0.002‡ | 12 (1.2%) | 11 (1.1%) | 0.9 | 0.834‡ |
| DM w/o complications | 5033 (16.5%) | 169 (15.9%) | 1.8 | 0.568‡ | 142 (14.4%) | 164 (16.6%) | 6.2 | 0.171‡ |
| DM w/complications | 3347 (11.0%) | 115 (10.8%) | 0.6 | 0.842‡ | 101 (10.3%) | 108 (11.0%) | 2.3 | 0.609‡ |
| Hemiplegia | 245 (0.8%) | 13 (1.2%) | 4.2 | 0.139‡ | 10 (1.0%) | 13 (1.3%) | 2.8 | 0.529‡ |
| Kidney disease | 450 (1.5%) | 66 (6.2%) | 24.8 | <0.001‡ | 57 (5.8%) | 61 (6.2%) | 1.7 | 0.704‡ |
| Leukemia | 381 (1.3%) | 85 (8.0%) | 32.5 | <0.001‡ | 67 (6.8%) | 53 (5.4%) | 5.9 | 0.187‡ |
| Liver disease | 3261 (10.7%) | 191 (17.9%) | 20.7 | <0.001‡ | 176 (17.9%) | 182 (18.5%) | 1.6 | 0.726‡ |
| Lymphoma | 930 (3.1%) | 135 (12.7%) | 36.3 | <0.001‡ | 122 (12.4%) | 109 (11.1%) | 4.1 | 0.363‡ |
| Myocardial infarction | 5439 (17.9%) | 158 (14.8%) | 8.2 | 0.011‡ | 165 (16.8%) | 155 (15.7%) | 2.8 | 0.541‡ |
| Peptic ulcer disease | 1541 (5.1%) | 56 (5.3%) | 0.9 | 0.773‡ | 39 (4.0%) | 53 (5.4%) | 6.7 | 0.135‡ |
| PVD | 1714 (5.6%) | 62 (5.8%) | 0.8 | 0.789‡ | 59 (6.0%) | 59 (6.0%) | 0.0 | 1.000‡ |
| Solid tumor | 3720 (12.2%) | 136 (12.8%) | 1.7 | 0.588‡ | 129 (13.1%) | 125 (12.7%) | 1.2 | 0.788‡ |
| Solid tumor w/metastases | 923 (3.0%) | 23 (2.2%) | 5.5 | 0.101‡ | 29 (2.9%) | 21 (2.1%) | 5.2 | 0.252‡ |
†
Equal variance t-test
‡
Chi-square test
§
Fisher exact test
Continuous variables presented as mean (standard deviation). Categorical variables presented as n (%).
AIDS – acquired immunodeficiency syndrome, CHF – congestive heart failure, DM – diabetes mellitus, INR – international normalized ratio, LMW – low molecular weight, PVD – peripheral vascular disease, SOFA – sequential organ failure assessment.